Skip to main content

Table 1 Data on EOC BM patients

From: Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients

Characteristics Risk factor Mean SD Median Q1 Q3 Min. Max.
Age at EOC diagnosis 52.6 9.3 54 47 59.3 27 67
  at SRT 56.3 9.2 56.5 50.8 62 35 77
Clinical CA125 before CT1 [U/mL] 1578 2317 740 151 1946 19 9693
  CA125 after CT1 [U/mL] 29 69 13 8 17 2 318
  CA125 before CT2 [U/mL] 566 791 190 84 690 38 2407
  CA125 after CT2 [U/mL] 73 143 22 10 57 9 496
  CA125 before SRT [U/mL] 132 189 56 25 139 8 533
  ZUBROD 1.2 0.4 1 1 1 1 3
  FIGO    IIIC IIIA IIIC IA IVA
  Tumor grade [G] 2.6 0.5 3 2 3 2 3
  Histopathology: adenocarcinoma serosum = 53%, adenocarcinoma endometroides = 25%, cystadenocarcinoma mucinosum = 6%, non-differentiated = 13%, not examined = 3%
Imaging No. of BMs at diagnosis 1.8 0.8 2 1 2 1 3
  Total PTV at diagnosis [cm3] 9.7 14.8 5.1 1.6 10.0 0.4 62.1
  Relapse out of CNS 47%       
  Localisation supratentorial = 25%, infratentorial = 63%, supratentorial/infratentorial = 12%
Treatment from EOC diagnosis to CT1 [weeks] 6.6 5.9 5 3 8 0 28
  CT1 duration [weeks] 19.6 5.6 18 17 20 12 38
  CT2 duration [weeks] 8.5 10.4 0 0 17 0 34
  Total CT duration (CT1 + CT2) [weeks] 27.7 13 23 18 35 12 72
  No. of CT1 cycles 6.1 0.8 6 6 6 5 9
  No. of CT2 cycles 2.4 2.9 0 0 5.5 0 9
  Total no. of CT cycles (CT1 + CT2) 8.5 3.2 6 6 11.5 5 18
  Surgery 22%       
  WBRT before SRT 53%       
  WBRT after SRT 16%       
  BM to SRT [months] 22 26.9 8 4.8 36 1 117
  BM to SRT (above 1 month) 75%       
Follow-up outcome from EOC diagnosis to BM [months] 29.5(CI95% = 25–44)    
  from BM to death [months] 16(CI95% = 8–21)    
  from SRS to death [months] 7(CI95% = 6–18)    
  from EOC diagnosis to death [months] 49(CI95% = 45–69)    
  Deaths during observation 94%